标题：三氧化二砷联合 ICE方案治疗复发难治非霍奇金淋巴瘤临床观察

      作者：曹海武，赵晓红，陆时运，周仲昊，王智
    ?（南京医科大学附属无锡市第二人民医院血液科，江苏 无锡 214002）

      卷次： 2016年27卷1期

      【摘要】 目的 探讨三氧化二砷联合 ICE方案(异环磷酰胺、顺铂、依托泊苷)治疗复发难治非霍奇金淋巴瘤
(NHL)的疗效和不良反应。方法 15例复发难治性NHL患者采用三氧化二砷联合 ICE方案化疗。异环磷酰胺
1.2 g/m2，静脉滴注，第1~4天；同时于异环磷酰胺后0 h、4 h和8 h应用美司那预防出血性膀胱炎，每次用量为当日
异环磷酰胺的20%，静脉注射；顺铂25 mg/m2，静脉滴注，第1~2天，足叶乙甙50 mg/m2，静脉滴注，第1~3天，亚砷酸
10 mg，静脉滴注，第5~18天；21~28 d为一个周期，每例患者至少完成两个周期以上治疗。观察疗效和不良反应。
结果 15例患者中完全缓解5例，部分缓解4例，疾病稳定4例，疾病进展2例，临床总有效率为60%。主要不良反
应为骨髓抑制，Ⅲ~Ⅳ度白细胞减少为12例(80.0%)。结论 三氧化二砷联合 ICE方案治疗复发难治性NHL临床效
果满意，值得临床推广。

      【关键词】 非霍奇金淋巴瘤；三氧化二砷；异环磷酰胺

      【中图分类号】 R730.263 【文献标识码】 A 【文章编号】 1003—6350（2016）01—0111—03


Clinical observation of arsenic trioxide in combination of ICE regimen for the treatment of patients with relapsed
and refractory non-Hodgkin lymphoma.
CAO Hai-wu, ZHAO Xiao-hong, LU Shi-yun, ZHOU Zhong-hao, WANG Zhi.
Department of Hematology, Wuxi NO.2 Hospital of Nanjing Medical University, Wuxi 2140002, Jiangsu, CHINA

【Abstract】 Objective To explore the clinical effect and side effect of patients with relapsed and refractory
non-Hodgkin lymphoma (NHL) treated by arsenic trioxide in combination of ICE regimen (ifosfamide, cisplatin, etopo-
side). Methods Fifteen patients with relapsed and refractory non-Hodgkin 1ymphoma were treated with arsenic triox-
ide in combination of ICE regimen (Ifosfamide 1.2 g/m2, intravenous drip, d1~4; At the same time, mesna was applied
to prevent hemorrhagic cystitis 0 h, 4 h and 8 h after ifosfamide, with dosage of 20% of that of ifosfamide, intravenous
injection; Cisplatin 25 mg/m2, intravenous drip, d1~2; Etoposide 50 mg/m2, intravenous drip, d1~3; Arsenic trioxid 10
mg, intravenous drip, d5~18; 21~28 d in one cycle). The clinica1 effect and side effect of patients who received at least 2
cycles were evaluated. Results In 15 cases, there were complete response (CR) in 5 cases (33.3%)，partial response
(PR) in 4 cases (26.7%), stable disease (SD) in 4 cases (26.7%), and progressive disease (PD) in 2 cases (13.3%). The to-
tal clinical effective rate was 60.0% (9/15). Major side effects was bone marrow suppression, and WHO gradeⅢ/Ⅳ leu-
kopenia were developed in 12 patients (80.0%). Conclusion Arsenic trioxide in combination of ICE regimen in the
treatment of relapsed and refractory non-Hodgkin lymphoma has satisfactory clinical results and is worthy of promotion.

      【Key words】 Non-Hodgkin lymphoma; Arsenic trioxide; Ifosfamide
·临床经验·
6350.2016.01.037